Haya Taitel
Directeur/Bestuurslid bij ENTERA BIO LTD.
Vermogen: 36 000 $ op 30-04-2024
Profiel
Haya Taitel is an Independent Director at Entera Bio Ltd.
since 2023.
Previously, she worked as the Chief Commercial Officer at Kadmon Holdings, Inc. from 2018 to 2021.
She completed her undergraduate degree at The Hebrew University of Jerusalem and her graduate degree at Temple University School of Pharmacy.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ENTERA BIO LTD.
0.05% | 01-03-2024 | 18 000 ( 0.05% ) | 36 000 $ | 30-04-2024 |
Actieve functies van Haya Taitel
| Bedrijven | Functie | Begin |
|---|---|---|
| ENTERA BIO LTD. | Directeur/Bestuurslid | 07-06-2023 |
Eerdere bekende functies van Haya Taitel
| Bedrijven | Functie | Einde |
|---|---|---|
| KADMON HOLDINGS, INC. | Corporate Officer/Principal | 01-11-2021 |
Opleiding van Haya Taitel
| Temple University School of Pharmacy | Graduate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENTERA BIO LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
